Unknown

Dataset Information

0

Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.


ABSTRACT: Sipuleucel-T is an autologous cellular immunotherapy that induces an immune response targeted against prostatic acid phosphatase (PAP) to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. In the phase III IMPACT study, sipuleucel-T was associated with a statistically significantly increased overall survival (OS) (median = 4.1?months) vs placebo. Patients with baseline prostate-specific antigen levels in the lowest quartile (?22.1?ng/mL) exhibited a 13-month improvement in OS with sipuleucel-T. Together, this led sipuleucel-T to be approved and recommended as first-line therapy in various guidelines for treatment of metastatic castration-resistant prostate cancer. This review discusses the varied findings about the mechanisms of action of sipuleucel-T, bringing them together to form a more coherent picture. These pieces include inducing a statistically significant increase in antigen-presenting cell activation; inducing a peripheral immune response specific to the target (PAP) and/or immunizing (PA2024) antigens; stimulating systemic cytotoxic T-lymphocyte activity; and mediating antigen spread (ie, increased antibody responses to secondary proteins in addition to PAP and PA2024). Each of these pieces individually correlates with OS. Sipuleucel-T also traffics T cells to the prostate and is associated with long-term immune memory such that a second course of treatment induces an anamnestic immune response. Prostate cancer does not have a strongly inflamed microenvironment, thus its response to immune checkpoint inhibitors is limited. Because sipuleucel-T is able to traffic T cells to the tumor, it may be an ideal combination partner with immunotherapies including immune checkpoint inhibitors or with radiation therapy.

SUBMITTER: Madan RA 

PROVIDER: S-EPMC7301097 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.

Madan Ravi A RA   Antonarakis Emmanuel S ES   Drake Charles G CG   Fong Lawrence L   Yu Evan Y EY   McNeel Douglas G DG   Lin Daniel W DW   Chang Nancy N NN   Sheikh Nadeem A NA   Gulley James L JL  

Journal of the National Cancer Institute 20200601 6


Sipuleucel-T is an autologous cellular immunotherapy that induces an immune response targeted against prostatic acid phosphatase (PAP) to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. In the phase III IMPACT study, sipuleucel-T was associated with a statistically significantly increased overall survival (OS) (median = 4.1 months) vs placebo. Patients with baseline prostate-specific antigen levels in the lowest quartile (≤22.1 ng/mL) exhibited a 13-m  ...[more]

Similar Datasets

| S-EPMC7930431 | biostudies-literature
| S-EPMC8572485 | biostudies-literature
| S-EPMC1716720 | biostudies-other
| S-EPMC8599550 | biostudies-literature
| S-EPMC7076116 | biostudies-literature
| S-EPMC8489306 | biostudies-literature
| S-EPMC4351045 | biostudies-literature
| S-EPMC8773466 | biostudies-literature
| S-EPMC10340546 | biostudies-literature
| S-EPMC3188788 | biostudies-literature